Today: 22 July 2026
Strategy shares rise after $109 million bitcoin buy funded by stock sale
29 December 2025
1 min read

Strategy shares rise after $109 million bitcoin buy funded by stock sale

NEW YORK, December 29, 2025, 10:03 ET — Regular session

  • Strategy shares rose after an SEC filing showed it bought 1,229 bitcoin last week for $108.8 million.
  • The company sold 663,450 Class A shares through its at-the-market program, raising the same $108.8 million in net proceeds.
  • Bitcoin slipped below $88,000; traders are watching crypto swings and Strategy’s pace of issuance.

Strategy Inc shares were up 1.1% at $160.60 in morning trade on Monday after the company disclosed a fresh bitcoin purchase funded by a sale of its own stock.

The update matters because Strategy’s equity has become a liquid stand-in for bitcoin exposure for stock investors, and its funding model relies heavily on issuing shares to buy more of the cryptocurrency.

With bitcoin still swinging sharply around year-end levels, the filing put renewed focus on how fast Strategy is adding to its holdings — and how much dilution investors may absorb along the way.

In a Form 8-K dated Dec. 29, the company said it sold 663,450 shares of its Class A common stock (MSTR) between Dec. 22 and Dec. 28 for net proceeds of $108.8 million.

That stock sale was executed under an at-the-market program, which lets a company sell shares into the open market over time at prevailing prices.

Strategy reported no sales during the week in its listed preferred-stock programs (STRF, STRC, STRK and STRD), and said it still had substantial capacity available for future issuance across those programs and its common stock.

The company said it acquired 1,229 bitcoin over the same period for $108.8 million, paying an average $88,568 per coin including fees and expenses.

As of Dec. 28, Strategy said it held 672,497 bitcoin bought for an aggregate $50.44 billion at an average purchase price of $74,997.

“The bitcoin purchases were made using proceeds from the sale of shares of MSTR Stock,” the filing said. SEC

Michael Saylor, Strategy’s executive chairman, confirmed the purchase in a post on X, writing: “Strategy has acquired 1,229 BTC for ~$108.8 million.” X (formerly Twitter)+1

Bitcoin was down about 0.8% at roughly $87,231, after earlier trading as high as $90,247, according to market data.

Other crypto-linked stocks were mixed: Coinbase Global was up about 0.5%, while bitcoin miner Marathon Digital rose about 2.6%.

Investors are likely to keep tracking bitcoin’s direction and any further updates to Strategy’s issuance and purchase cadence, with the company’s regular disclosures offering near-term signposts on how aggressively it is deploying fresh equity proceeds into bitcoin.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • John Catsimatidis Sees Oil Price Surge as Short-Lived Despite Mideast Concerns
    July 22, 2026, 1:38 PM EDT. John Catsimatidis, CEO of Gristedes, described the recent oil price surge sparked by Middle East unrest as a temporary issue during an appearance on 'Varney & Co.' He expects oil prices to decline even as worries tied to the Iran conflict persist, and commented as well on New York City Mayor Zohran Mamdani's private housing proposal.
HFCL jumps 10% on heavy volumes even as MarketsMojo keeps “Strong Sell” callNEW YORK, December 29, 2025, 00:11 ET
Previous Story

HFCL jumps 10% on heavy volumes even as MarketsMojo keeps “Strong Sell” callNEW YORK, December 29, 2025, 00:11 ET

Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs
Next Story

Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs

Go toTop